Transient Inhibition of TrkB Kinase after Status Epilepticus Prevents Development of Temporal Lobe Epilepsy

Temporal lobe epilepsy is the most common and often devastating form of human epilepsy. The molecular mechanism underlying the development of temporal lobe epilepsy remains largely unknown. Emerging evidence suggests that activation of the BDNF receptor TrkB promotes epileptogenesis caused by status epilepticus. We investigated a mouse model in which a brief episode of status epilepticus results in chronic recurrent seizures, anxiety-like behavior, and destruction of hippocampal neurons. We used a chemical-genetic approach to selectively inhibit activation of TrkB. We demonstrate that inhibition of TrkB commencing after status epilepticus and continued for 2 weeks prevents recurrent seizures, ameliorates anxiety-like behavior, and limits loss of hippocampal neurons when tested weeks to months later. That transient inhibition commencing after status epilepticus can prevent these long-lasting devastating consequences establishes TrkB signaling as an attractive target for developing preventive treatments of epilepsy in humans.

[1]  E. Magri,et al.  Localized delivery of fibroblast growth factor–2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model , 2009, Proceedings of the National Academy of Sciences.

[2]  W. Löscher,et al.  Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice , 2007, Experimental Neurology.

[3]  B Greger,et al.  A Simple Quantitative Method for Analyzing Electrographic Status Epilepticus in Rats Electrode Implantation , 2022 .

[4]  H. Steinbusch,et al.  TrkB inhibition as a therapeutic target for CNS-related disorders , 2012, Progress in Neurobiology.

[5]  M R Segal,et al.  A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. , 2001, The New England journal of medicine.

[6]  Joshua E. Motelow,et al.  Early treatment suppresses the development of spike‐wave epilepsy in a rat model , 2008, Epilepsia.

[7]  J. McNamara,et al.  The cellular and synaptic location of activated TrkB in mouse hippocampus during limbic epileptogenesis , 2013, The Journal of comparative neurology.

[8]  A. Wilfong,et al.  Treating Epilepsy in Tuberous Sclerosis with Everolimus: Getting Closer , 2014, Epilepsy currents.

[9]  R. Dingledine,et al.  Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model , 2003, Experimental Neurology.

[10]  G. V. Goddard,et al.  A permanent change in brain function resulting from daily electrical stimulation. , 1969, Experimental neurology.

[11]  A. Pitkänen,et al.  Atipamezole, an α2-adrenoceptor antagonist, has disease modifying effects on epileptogenesis in rats , 2004, Epilepsy Research.

[12]  Xi Chen,et al.  A Chemical-Genetic Approach to Studying Neurotrophin Signaling , 2005, Neuron.

[13]  M. Hascöet,et al.  The mouse light/dark box test. , 2003, European journal of pharmacology.

[14]  毛利 元信 Unilateral hippocampal CA3-predominant damage and short latency epileptogenesis after intra-amygdala microinjection of kainic acid in mice , 2010 .

[15]  J. McNamara,et al.  Conditional Deletion of TrkB but Not BDNF Prevents Epileptogenesis in the Kindling Model , 2004, Neuron.

[16]  O. P. Ottersen,et al.  Injections of kainic acid into the amygdaloid complex of the rat: An electrographic, clinical and histological study in relation to the pathology of epilepsy , 1980, Neuroscience.

[17]  D. Dinner,et al.  Mesial temporal lobe epilepsy. , 1995, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[18]  W. Hauser,et al.  Factors prognostic of unprovoked seizures after febrile convulsions. , 1987, The New England journal of medicine.

[19]  Donncha F. O’Brien,et al.  Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects , 2012, Nature Medicine.

[20]  T. Sutula,et al.  Repeated brief seizures induce progressive hippocampal neuron loss and memory deficits. , 2002, Progress in brain research.

[21]  R. Segal,et al.  Differential Utilization of Trk Autophosphorylation Sites* , 1996, The Journal of Biological Chemistry.

[22]  D. Spencer,et al.  Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination , 1993, Annals of neurology.

[23]  M. Wong Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies , 2010, Epilepsia.

[24]  W. Tatum Mesial Temporal Lobe Epilepsy , 2012, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[25]  Markus Reuber,et al.  Anxiety in patients with epilepsy: Systematic review and suggestions for clinical management , 2005, Epilepsy & Behavior.

[26]  R. Torta,et al.  Behavioral, Psychotic, and Anxiety Disorders in Epilepsy: Etiology, Clinical Features, and Therapeutic Implications , 1999, Epilepsia.

[27]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[28]  David C. Henshall,et al.  Unilateral hippocampal CA3-predominant damage and short latency epileptogenesis after intra-amygdala microinjection of kainic acid in mice , 2008, Brain Research.

[29]  A. Pitkänen Therapeutic approaches to epileptogenesis—Hope on the horizon , 2010, Epilepsia.

[30]  A. Dörfler,et al.  Structural brain imaging. , 2012, Handbook of clinical neurology.

[31]  C. Bernard,et al.  Neuron‐restrictive silencer factor‐mediated hyperpolarization‐activated cyclic nucleotide gated channelopathy in experimental temporal lobe epilepsy , 2011, Annals of neurology.

[32]  Michael Davis,et al.  Brain-Derived Neurotrophic Factor and Tyrosine Kinase Receptor B Involvement in Amygdala-Dependent Fear Conditioning , 2004, The Journal of Neuroscience.

[33]  Yunfei Huang,et al.  Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy , 2010, Neurobiology of Disease.

[34]  D. Brody,et al.  Rapamycin Attenuates the Development of Posttraumatic Epilepsy in a Mouse Model of Traumatic Brain Injury , 2013, PloS one.

[35]  Y. Chuang,et al.  Factors predictive of outcome in patients with de novo status epilepticus. , 2009, QJM : monthly journal of the Association of Physicians.

[36]  S. Spencer,et al.  Hippocampal sclerosis , 1995, Neurology.

[37]  E. Huang,et al.  Trk receptors: roles in neuronal signal transduction. , 2003, Annual review of biochemistry.

[38]  Joe Z Tsien,et al.  Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain , 2003, Proceedings of the National Academy of Sciences of the United States of America.